Immorna is a biotechnology company that develops therapeutics and vaccines based on its RNA platforms, including conventional, self-replicating and circular RNA. The company has built a robust CMC platform for RNA synthesis, purification, and analytical testing that is well suited for clinical and commercial development. Immorna offers one-stop-shop contract development manufacturing (CDMO) services, based on its proprietary RNA and LNP platforms.
The company raised nearly $100 million in series A+ and A++ financing rounds to speed up the clinical development and commercialization of its RNA-based therapeutics. Immorna’s competitors include Slingshot Biosciences, Verismo Therapeutics, and Cabaletta Bio.
The company raised nearly $100 million in series A+ and A++ financing rounds to speed up the clinical development and commercialization of its RNA-based therapeutics. Immorna’s competitors include Slingshot Biosciences, Verismo Therapeutics, and Cabaletta Bio.
Employees: 11-50
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | China Grow... | en.cgcvc.c... |
Mentions in press and media 6
| Date | Title | Description |
| 08.07.2024 | Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors | MORRISVILLE, NC., July 8, 2024 /PRNewswire/ -- Immorna Biotherapeutics, Inc. (Immorna), a clinical stage biotechnology company developing both self-replicating and conventional mRNA-based therapeutics and vaccines, announced today that the ... |
| 30.05.2023 | Immorna Announces First Subject Dosed in a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Vaccine Developed for the Prevention of Shingles | MORRISVILLE, N.C., May 30, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the first subject has been dosed in t... |
| 27.02.2023 | Chinese biotech firm Immorna raises $100m in extended Series A rounds | Immorna, a Chinese developer of mRNA-based therapeutics, has snapped up $100 million in Series A+ and A++ rounds in a bid to support the clinical development of its drug candidates, according to an announcement on Monday. China Structural R... |
| 09.01.2023 | Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine | MORRISVILLE, N.C., Jan. 9, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the U.S. Food and Drug Administratio... |
| 21.11.2022 | Immorna Receives IND Clearance to Conduct a Phase 1/2 Study of JCXH-221, a Broadly Protective mRNA-Based COVID-19 Vaccine | MORRISVILLE, N.C., Nov. 21, 2022 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the U.S. Food and Drug Administrati... |
| - | Immorna | “Immorna Jiachen West Sea ” |